The DESolve^® Novolimus Bioresorbable Scaffold

References

• Schmidt T , AbbottJD. Coronary stents: history, design, and construction. J. Clin. Med., 7, 126 (2018).
   PubMed Web of Science ®Google Scholar
• Vahl TP , GasiorP, GongoraCAet al. Four-year polymer biocompatibility and vascular healing profile of a novel ultrahigh molecular weight amorphous PLLA bioresorbable vascular scaffold: an OCT study in healthy porcine coronary arteries. Euro Interven., 12, 1510–1518 (2016).
   Google Scholar
• Gonzalo N , OtaeguiI, RumorosoJRet al. Device specificity of vascular healing following implantation of bioresorbable vascular scaffolds and bioabsorbable polymer metallic drug-eluting stents in human coronary arteries: the ESTROFA OCT BVS vs. BP-DES study. Euro Interven., 14, e1295–e1303 (2018).
   Google Scholar
• Neumann FJ , Sousa-UvaM, AhlssonAet al. ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J., 40(2), 87–165 (2019).
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ , OnumaY, SerruysPW, StoneGW. Bioresorbable vascular scaffolds for coronary revascularization. Circulation, 134, 168–182 (2016).
   PubMed Web of Science ®Google Scholar
• Montone RA , NiccoliG, DeMarco Fet al. Temporal trends in adverse events after everolimus-eluting bioresorbable vascular scaffold versus everolimus-eluting metallic stent implantation: a meta analysis of randomized controlled trials. Circulation, 135, 2145–2154 (2017).
   PubMed Web of Science ®Google Scholar
• Zhang XL , ZhuQQ, KangLNet al. Mid- and long-term outcome comparisons of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents: a systematic review and meta-analysis. Ann. Intern. Med., 167, 642–654 (2017).
   PubMed Web of Science ®Google Scholar
• Gheorghe L , MillánX, Jimenez-KockarMet al. Bioresorbable vascular scaffolds in coronary chronic total occlusions: clinical, vasomotor and optical coherence tomography findings at three-year follow-up (ABSORB-CTO study). Euro Interven., 15, 99–107 (2019).
   Google Scholar
• Mori H , VirmaniR, FinnAV. Bioresorbable vascular scaffolds: implication of very late scaffold thrombosis. Coron. Artery Dis., 28, 533–538 (2017).
   PubMed Web of Science ®Google Scholar
• Alfonso F , CuestaJ. Bioresorbable vascular scaffolds restenosis: pathophysiology and predictors. JACC Cardiovasc. Interv., 10, 1828–1831 (2017).
   PubMed Web of Science ®Google Scholar
• Verheye S , OrmistonJA, StewartJet al. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc. Interv., 7(1), 89–99 (2014).
   PubMed Web of Science ®Google Scholar
• Foin N , LeeR, MattesiniAet al. Bioabsorbable vascular scaffold overexpansion: insights from in vitro post-expansion experiments. Euro Interven., 11(12), 1389–1399 (2016).
   Google Scholar
• Oberhauser JP , HossainyS, RapozaRJ. Design principles and performance of bioresorbable polymeric vascular scaffolds. Euro Interven., 5(Suppl. F), F15–F22 (2009).
   Google Scholar
• Eglin D , AliniM. Degradable polymeric materials for osteosynthesis: tutorial. Eur. Cell Mater., 16, 80–91 (2008).
   PubMed Web of Science ®Google Scholar
• Ang HY , BulluckH, WongPet al. Bioresorbable stents: current and upcoming bioresorbable technologies. Int. J. Cardiol., 228, 931–9 (2017).
   PubMed Web of Science ®Google Scholar
• Ormiston J , WebberB, UbodBet al. An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition). Euro Interven., 11, 60–67 (2015).
   Google Scholar
• Schmidt W , BehrensP, Brandt-WunderlichCet al. In vitro performance investigation of bioresorbable scaffolds – standard tests for vascular stents and beyond. Cardiovasc. Revasc. Med., 17, 375–383 (2016).
   PubMed Web of Science ®Google Scholar
• Onuma Y , SerruysPW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?Circulation, 123, 779–797 (2011).
   PubMed Web of Science ®Google Scholar
• Glagov S , WeisenbergE, ZarinsCKet al. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med., 316(22), 1371–1375 (1987).
   PubMed Web of Science ®Google Scholar
• Wiebe J , BauerT, DoerrOet al. Implantation of a novolimus-eluting bioresorbable scaffold with a strut thickness of 100 μm showing evidence of self-correction. Euro Intervention, 11(2), 204 (2015).
   Google Scholar
• Abizaid A , CostaRA, SchoferJet al. Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. JACC Cardiovasc Interv., 9, 565–74 (2016).
   PubMed Web of Science ®Google Scholar
• Nef H , HauptmannKE, LatibAet al. TCT-515 multi-center, post-marketing evaluation of the elixir DESolve novolimus eluting bioresorbable coronary stent system: 6-month results from the DESolve PMCF study. J. Am. Coll. Cardiol., 66, B210 (2015).
   Web of Science ®Google Scholar
• Boeder NF , DörrO, BauerTet al. Effect of plaque composition, morphology, and burden on DESolve novolimus-eluting bioresorbable vascular scaffold expansion and eccentricity – an optical coherence tomography analysis. Cardiovasc. Revasc. Med., 20(6), 480–484 (2019).
   PubMed Web of Science ®Google Scholar
• Mattesini A , BoederN, ValenteSet al. Absorb vs. DESolve: an optical coherence tomography comparison of acute mechanical performances. Euro Intervention, 12(5), e566–e573 (2016).
   Google Scholar
• Nef HM , WiebeJ, SchmidtGet al. Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome. Herz., 45(Suppl. 1), 95–104 (2019).
   PubMed Web of Science ®Google Scholar
• Nef H , WiebeJ, BoederNet al. A multicenter post-marketing evaluation of the Elixir DESolve® novolimus-eluting bioresorbable coronary scaffold system: first results from the DESolve PMCF study. Catheter. Cardiovasc. Interv. 15; 92(6), 1021–1027 (2018).
   PubMed Web of Science ®Google Scholar
• Foin N , MattesiniA, WongPet al. Bioresorbable scaffold thrombosis: why BRS size matters. J. Am. Coll. Cardiol., 68, 571–572 (2016).
   PubMed Web of Science ®Google Scholar
• Byrne RA , StefaniniGG, CapodannoDet al. Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. Eur. Heart J., 39(18), 1591–1601 (2018).
   PubMed Web of Science ®Google Scholar
• Mattesini A , BartoliniS, SoriniDini Cet al. The DESolve novolimus bioresorbable Scaffold: from bench to bedside. J. Thorac. Dis., 9(Suppl. 9), S950–S958 (2017).
   PubMedGoogle Scholar